• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Lisata Therapeutics, Inc. - Common Stock (NQ:LSTA)

    5.000 +0.000 (+0.00%)
    Streaming Delayed Price Updated: 11:43 AM EDT, Apr 7, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Lisata Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 Next >
    News headline image
    Halper Sadeh LLC is Investigating Whether TALK, UBFO, LSTA are Obtaining Fair Deals for their Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    News headline image
    Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Halper Sadeh LLC Reminds Shareholders of SKYT, NATH, SNCY, LSTA of the Firm’s Investigations
    Shareholders should contact the firm as there may be limited time to enforce your rights 
    From Halper Sadeh LLC
    Via GlobeNewswire
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: SkyWater Technology, Inc. (Nasdaq - SKYT), Nathan’s Famous, Inc. (Nasdaq – NATH), Lisata Therapeutics, Inc. (Nasdaq – LSTA), Sun Country Airlines Holdings, Inc.
    From Brodsky & Smith LLC
    Via GlobeNewswire
    News headline image
    Halper Sadeh LLC Encourages NATH, PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights
    Shareholders should contact the firm as there may be limited time to enforce your rights 
    From Halper Sadeh LLC
    Via GlobeNewswire
    News headline image
    Halper Sadeh LLC Encourages SKYT, NATH, LSTA Shareholders to Contact the Firm to Discuss Their Rights
    From Halper Sadeh LLC
    Via GlobeNewswire
    News headline image
    Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide
    Lisata regains full development rights to certepetide in the Greater China Region 
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    LSTA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Lisata Therapeutics, Inc. is Fair to Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nathan’s Famous, Inc. (Nasdaq – NATH), Lisata Therapeutics, Inc. (Nasdaq – LSTA), Sun Country Airlines Holdings, Inc. (Nasdaq - SNCY), Ventyx Biosciences, Inc.
    From Brodsky & Smith LLC
    Via GlobeNewswire
    News headline image
    Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year’
    Annual Awards Program Recognizes Breakthrough Life Sciences & Biotechnology Innovation Around the World 
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent
    Data from Catalent’s preclinical studies evaluating certepetide as a SMARTag® ADC payload showed both improved tumor selective penetration and efficacy 
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update
    Compelling new preliminary data consistent with previously reported preclinical findings demonstrating certepetide’s potential ability to enhance the effectiveness of immunotherapy 
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata’s Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Lisata Therapeutics to Present at the 2025 BIO International Convention
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Lisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Lisata Therapeutics Announces Research License with Catalent
    Catalent to evaluate certepetide with its SMARTag® antibody-drug conjugate platform 
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Lisata Therapeutics to Present at the Investival Showcase USA
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Lisata Therapeutics and GATC Health Consummate First Step in Strategic Collaboration to use AI to Derisk and Accelerate Drug Development
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.